Research Investigator on the NIH-awarded Radiation-Induced Cardiopulmonary Injury in Humans project.
As of 2008 · Last known relationship
Michael August Blazing is a Duke cardiology faculty leader whose work connects cardiovascular prevention, evidence-based treatment, and care for patients with difficult-to-manage cholesterol, hypertension, and heart failure. He earned an M.D. from the University of California San Francisco in 1987, completed internal medicine residency there from 1987 to 1990, and completed cardiology training at Duke University Medical Center from 1991 to 1995. He has been Associate Professor of Medicine at Duke since 2007 and is director of Outpatient Services for the Duke cardiology practice. His research focuses on primary and secondary prevention, hypercholesterolemia, statin treatment, and analysis of discharge data. Earlier Duke roles included assistant professor of medicine and director of Duke’s Cardiac Outpatient Clinic.
Each topic is linked to its supporting source in Sources.
Training includes Research Investigator on the NIH-awarded Radiation-Induced Cardiopulmonary Injury in Humans project., Research Co-Investigator on the NIH-awarded Anxiety, Depression, and Non-Cardiac Chest Pain project., Cardiology residency at Duke University Medical Center, and Internal Medicine residency at University of California–San Francisco Medical Center, plus 11 more records.
Explore education and trainingAs of 2008
As of 2007
As of 1995
As of 1990
As of 1987
As of 2007
Assessment of adverse effects attributed to statin therapy in product labels: a meta-analysis of double-blind randomised controlled trials[4]
2026
Association of Apolipoprotein B-Containing Lipoproteins and Risk of Myocardial Infarction in Individuals With and Without Atherosclerosis: Distinguishing Between Particle Concentration, Type, and Content[4]
2022
Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT[4]
2022
Cardiovascular Events and Long-Term Risk of Sudden Death Among Stabilized Patients After Acute Coronary Syndrome: Insights From IMPROVE-IT[4]
2022
Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials[4]
2022
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis[4]
2024
Grant: Anxiety, Depression, and Non-Cardiac Chest Pain, awarded by the National Institutes of Health.[4]
2001 to 2007
Grant: Radiation-Induced Cardiopulmonary Injury in Humans, awarded by the National Institutes of Health.[4]
1996 to 2008
Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis[4]
2023
Impact of Ezetimibe on New-Onset Diabetes: A Substudy of IMPROVE-IT[4]
2023
In-Hospital Virtual Peer-to-Peer Consultation to Increase Guideline-Directed Medical Therapy for Heart Failure: A Pilot Randomized Trial[4]
2023
Primary prevention, secondary prevention, hyperlipidemia, homocysteine, and hypertension.[4]
Research interests include hypercholesterolemia treatment in elderly patients, statin effects on lipid profiles, and early treatment of hypercholesterolemia after myocardial infarction.[4]
Research interests in primary and secondary prevention of cardiovascular disease, including evidence-based treatment, secondary prevention, and analysis of discharge data.[4]
Why Novel Therapies in Preventive Cardiology May Face a Marathon, Not a Sprint[4]
2023